Jun. 22, 2011
On June 23, 2011 Sirnaomics, a Maryland company, announced its partnership with Guangdong Zhongsheng Pharma to develop its small interfering RNA (siRNA) ocular neovascularization therapeutic drug. The partnership will seek to develop and commercialize STP601, a Sirnaomics siRNA candidate for treatment of diabetic retinopathy and age-related macular degeneration.
Zhongsheng Pharma has committed an investment of $9.8 million in the partnership, including upfront and milestone payments.
This is the second transaction Sirnomics is executing in China.